Product Description
GC1109 targets as its antigen the anthrax toxin which, in infection, serves as a receptor binder.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Green Cross
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Anthrax
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GC1109 | P2 |
Completed |
Anthrax |
2022-08-02 |
24% |
| GC1109_P1_v1.2 | P1 |
Completed |
Anthrax |
2009-12-01 |